Therapeutic Response
ER positive, HER2-positive, and PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
Statements
| Source and description |
|---|
ER positive, HER2-positive, and PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
| Source and description |
|---|